Thus, COVID-19 coagulopathies are characterized by the presence of multiple autoantibodies besides anti-CL that include anti-β2GPI, anti-platelet factor 4 (PF4), anti-phosphatidylserine/prothrombin (aPS/PT), and anti-lupus coagulant (anti-La antigens), which are not usually present in MIS-C or KD. Here, PF4 is linked to blood coagulation disease.